Differential cytostatic activity of monocyte-derived cytokines against human melanoma cells.
We investigated the capacity of 3 major cytokines secreted by activated monocytes, IL-1 beta, TNF alpha and IL-6, to inhibit growth of melanoma tumor cells. Using neutralizing antibodies against IL-1 beta, TNF alpha and IL-6, we observed that the cytostatic activity against A375 melanoma cells is largely due to the presence of IL-6 in culture supernatants of monocytes stimulated with LPS. A375 cells appeared to be extremely sensitive to monocyte-derived cytokines, since in addition to rIL-6 also rIL-1 beta and rTNF alpha displayed cytostatic activity against A375 cells. We observed additive or synergistic cytostatic effects upon use of combinations of these cytokines. When 7 other melanoma cell lines and short-term melanoma cultures were tested and compared with A375, a major difference in their sensitivity to monocyte-derived cytokines were observed. Although 7 out of 8 melanoma cell lines were sensitive to culture supernatants of monocytes stimulated with LPS, significant differences were found when recombinant cytokines were used. The widely used A375 was the only melanoma cell line sensitive to rIL-1 beta, rTNF alpha and rIL-6. The growth of none of the other 7 melanoma cell cultures was significantly affected by rIL-1 beta. Seven out of 8 melanoma cell cultures were sensitive to rTNF alpha and 3 out of 8 to rIL-6. The results of our study indicate that the sensitivity of melanoma cell cultures for different monocyte-derived cytokines is highly variable, and that it is questionable whether the A375 melanoma cell line, sensitive to rIL-1 beta, rTNF alpha and rIL-6, is representative for melanoma.
te Velde
A A
AA
Division of Immunology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Huis, Amsterdam.
vd Wiel-v Kemenade
E
E
Figdor
C G
CG
D002455:Cell Division / Q000187:drug effects; D004357:Drug Synergism; D006801:Humans; D007375:Interleukin-1 / Q000494:pharmacology*; D015850:Interleukin-6 / Q000494:pharmacology*; D008070:Lipopolysaccharides; D008545:Melanoma / Q000473:pathology*; D009000:Monocytes / Q000502:physiology*; D011994:Recombinant Proteins / Q000494:pharmacology; D014407:Tumor Cells, Cultured; D014409:Tumor Necrosis Factor-alpha / Q000494:pharmacology*
D007375:Interleukin-1; D015850:Interleukin-6; D008070:Lipopolysaccharides; D011994:Recombinant Proteins; D014409:Tumor Necrosis Factor-alpha